Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

J&J Innovative Medicine Medical AffairsJ&J Innovative Medicine Medical Affairs
VS
Intas PharmaceuticalsIntas Pharmaceuticals
J&J Innovative Medicine Medical Affairs

J&J Innovative Medicine Medical Affairs

920 US-202, Raritan, New Jersey, US, 08869

Last Update: 22/04/2026

View Profile
749/1000Moderate

The goal of the J&J Innovative Medicine Medical Affairs LinkedIn page is to share oncology, immunology, and neuroscience-related medical & scientific information with US healthcare professionals (HCPs). We will share information about scientific data presented at medica...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:2
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0
Intas Pharmaceuticals

Intas Pharmaceuticals

Sarkhej Gandhinagar Highway, Near Sola Bridge, Ahmedabad, Gujarat, IN

Last Update: 01/04/2026

View Profile
Between 750 and 799
https://intaspharma.com
795/1000Fair

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of su...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:18,773
Subsidiaries:1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
J&J Innovative Medicine Medical Affairs

J&J Innovative Medicine Medical Affairs

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Intas Pharmaceuticals

Intas Pharmaceuticals

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for J&J Innovative Medicine Medical Affairs in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incidents

Incident History - J&J Innovative Medicine Medical Affairs (X = Date, Y = Severity)

J&J Innovative Medicine Medical Affairs cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Intas Pharmaceuticals (X = Date, Y = Severity)

Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
J&J Innovative Medicine Medical Affairs

J&J Innovative Medicine Medical Affairs

Incidents
No explicit notable incidents reported.
Intas Pharmaceuticals

Intas Pharmaceuticals

Incidents
No explicit notable incidents reported.

FAQ

Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has the best AI Cybersecurity Score ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has experienced more cyber incidents in the past ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has experienced more cyber incidents this year ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has experienced at least one ransomware attack ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has experienced at least one data breach ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has experienced at least one targeted cyberattack ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has experienced at least one vulnerability ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one holds the most compliance certifications ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one holds the fewest compliance certifications ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has the most subsidiaries ?
Between J&J Innovative Medicine Medical Affairs company and Intas Pharmaceuticals company, which one has the largest number of employees ?
Between J&J Innovative Medicine Medical Affairs and Intas Pharmaceuticals, which company holds both SOC 2 Type 1 certifications ?
Between J&J Innovative Medicine Medical Affairs and Intas Pharmaceuticals, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - J&J Innovative Medicine Medical Affairs or Intas Pharmaceuticals ?
Which company is PCI DSS compliant - J&J Innovative Medicine Medical Affairs or Intas Pharmaceuticals ?
Between J&J Innovative Medicine Medical Affairs and Intas Pharmaceuticals, which company complies with HIPAA regulations for healthcare data ?
Between J&J Innovative Medicine Medical Affairs and Intas Pharmaceuticals, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-63261
SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-63260
SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-63259
SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-63145
SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-63144
SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8